The release studies are performed with the nanocarrier prepared and characterized in the manner described previously. By definition, this parameter essentially refers to the amount of drug released per unit of time from the CSHN systems and can be determined using dialysis membrane (also known as the static method) and ultracentrifugation . These assays are endpoint assays in which the drugs released from the nanocarriers are collected at a series of time points and then quantified using UV-Vis and HPLC, as mentioned earlier. In this way, the potential release profile of nanocarriers can be estimated under in vivo conditions.